Biotechnology

A legal battle over the blockbuster cancer drug Jemperli escalates, with billions in future royalties and a company's strategic future on the line.

With a new CEO from Illumina and Exact Sciences, Quanterix signals a strategic shift from tech development to aggressive market and clinical expansion.

Savara's potential new therapy for autoimmune PAP, MOLBREEVI, gets a powerful partner in PANTHERx Rare, promising a new era of comprehensive patient care.

The first system pairing a one-year implantable glucose monitor with an automated insulin pump is now available, promising to transform daily life for people with diabetes.

Alessa Therapeutics’ rice-sized implant, Enolen, earns FDA Fast Track, promising a new era for prostate cancer therapy without debilitating side effects.

MiNK Therapeutics and UW–Madison launch a trial for an 'off-the-shelf' cell therapy, aiming to prevent deadly Graft-Versus-Host Disease (GvHD).

Paris-based Enodia Therapeutics lands €20.7M to advance its AI platform that degrades disease-causing proteins at the point of synthesis, targeting new cures.

New research reveals a stark disconnect between clinical views and patient reality in atopic dermatitis, with millions suffering severe, overlooked impacts.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

Global consulting giant Andersen partners with niche firm Scimitar to tackle pharma's biggest challenges, signaling a new model for expertise at scale.

A new class of painkillers promises the power of opioids with a far lower risk of addiction. Tris Pharma's cebranopadol could reshape pain management.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

With pivotal data for its sickle cell drug and a new myelofibrosis program, Cellarity's AI-driven 'Cell State-Correcting' platform faces a crucial test.

With multiple clinical trials advancing and a savvy global expansion, RESTEM is poised to challenge the treatment paradigm for autoimmune disorders.

Safi Biotherapeutics and ARMI | BioFabUSA achieve a critical step toward mass-producing red blood cells, offering hope for patients and military readiness.

A new partnership leverages in vivo screening to find novel obesity targets, aiming to revolutionize a market projected to exceed $100 billion.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.

After 30 years, CEO Jim Foster will retire, passing the torch to COO Birgit Girshick in a move that signals continuity and a new era of governance.

Klotho Neurosciences will present its novel gene therapy for Alzheimer's and ALS at a key summit, seeking to turn scientific promise into clinical reality.